Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.92 [0.77, 1.10] | | < 1 | | 50% | 2 studies (2/-) | 82.2 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.82 [0.71, 0.94] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.89 [0.60, 1.32] | | < 1 | | 0% | 1 study (1/-) | 71.3 % | NA | not evaluable | | important | - |
DOR | 0.19 [0.12, 0.30] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
objective responses (ORR) | 0.61 [0.24, 1.56] | | > 1 | | 93% | 2 studies (2/-) | 15.2 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 0.24 [0.09, 0.66] | | < 1 | | 56% | 2 studies (2/-) | 99.7 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) | 0.31 [0.05, 2.00] | | < 1 | | 99% | 2 studies (2/-) | 88.9 % | some concern | not evaluable | moderate | non important | - |
AE leading to death (grade 5) | 1.23 [0.71, 2.13] | | < 1 | | 33% | 2 studies (2/-) | 22.8 % | some concern | not evaluable | moderate | non important | - |
AE leading to treatment discontinuation (any grade) | 0.22 [0.08, 0.62] | | < 1 | | 90% | 2 studies (2/-) | 99.8 % | some concern | not evaluable | moderate | non important | - |
SAE (any grade) | 0.85 [0.70, 1.04] | | < 1 | | 0% | 2 studies (2/-) | 94.5 % | some concern | not evaluable | moderate | non important | - |
STRAE (any grade) | 0.49 [0.35, 0.67] | | < 1 | | 37% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (any grade) | 0.14 [0.03, 0.55] | | < 1 | | 95% | 2 studies (2/-) | 99.7 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.12 [0.02, 0.89] | | < 1 | | 99% | 2 studies (2/-) | 98.0 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 0.55 [0.22, 1.39] | | < 1 | | 0% | 2 studies (2/-) | 89.8 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 0.22 [0.12, 0.38] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Anaemia TRAE (grade 3-4) | 0.19 [0.03, 1.02] | | < 1 | | 77% | 2 studies (2/-) | 97.3 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.48 [0.24, 0.95] | | < 1 | | 0% | 2 studies (2/-) | 98.2 % | some concern | not evaluable | moderate | non important | - |
Constipation TRAE (grade 3-4) | 0.02 [0.00, 0.38] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 2.21 [0.20, 24.48] | | < 1 | | 0% | 1 study (1/-) | 26.1 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.42 [0.19, 0.92] | | < 1 | | 0% | 2 studies (2/-) | 98.4 % | some concern | not evaluable | moderate | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.04 [0.00, 0.27] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.27 [0.01, 6.11] | | < 1 | | 0% | 1 study (1/-) | 79.0 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.03 [0.01, 0.12] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.12 [0.01, 0.95] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 1.10 [0.02, 55.68] | | < 1 | | 0% | 1 study (1/-) | 48.1 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 4.43 [0.20, 98.49] | | < 1 | | 0% | 1 study (1/-) | 17.7 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.08 [0.01, 0.58] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Anaemia AE (grade 3-4) | 0.08 [0.05, 0.13] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.51 [0.24, 1.10] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.22 [0.09, 0.54] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Febrile neutropenia AE (grade 3-4) | 0.05 [0.00, 0.92] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 0.54 [0.18, 1.61] | | < 1 | | 0% | 1 study (1/-) | 86.4 % | NA | not evaluable | | non important | - |
Leucopenia AE (grade 3-4) | 0.02 [0.00, 0.25] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.08 [0.01, 0.58] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 0.00 [0.00, 0.05] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.01 [0.00, 0.10] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.10 [0.01, 0.76] | | < 1 | | 0% | 1 study (1/-) | 98.6 % | NA | not evaluable | | non important | - |